Navigation Links
Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
Date:6/11/2013

LA JOLLA, Calif., June 11, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has named Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors effective immediately. 

Dr. Papadopoulos assumes the role of Chairman of the Board from John Maraganore, Ph.D., who will remain a member of the Board of Directors. Dr. Papadopoulos, who has been a member of the Board since 2008, has more than 30 years of experience in the biotechnology and pharmaceutical industries as an investment banker, board member, company founder and investor. Dr. Papadopoulos is a Board member of several companies including Biogen Idec, Inc. and Exelixis, Inc., where he is Chairman.

"Stelios brings together financial savvy, business ingenuity and scientific creativity," said John Maraganore, Ph.D., member of the Board and President and CEO of Alnylam Pharmaceuticals, Inc.  "I couldn't think of a more accomplished individual to become Chairman of Regulus' Board." 

"Stelios' transition to Chairman of the Board comes at a very exciting time for Regulus," said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus.  "We've achieved early success under our 'Road to the Clinic' strategy with the recent nomination of our first clinical candidate, RG-101 for the treatment of HCV.  Stelios' extensive industry knowledge and experience are perfectly suited to help advance our microRNA candidates into clinical development and position Regulus for continued success and growth."

"Regulus is a benchmark of innovation focused on harnessing the power of a transformative class of novel therapeutics and biomarkers based on microRNAs," said Stelios Papadopoulos, Ph.D., Chairman of the Board.  "I am excited to help guide our dedicated and talented team as we strive to execute on Regulus' scientific and strategic goals." 

Dr. Papadopoulos retired as Vice Chairman of Cowen and Company, LLC in 2006 after six years with the firm where he was an investment banker focused on the biotechnology and pharmaceuticals sectors.  Prior to joining Cowen in 2000, Dr. Papadopoulos was an investment banker at PaineWebber Incorporated, most recently serving as Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology.  Prior to that, he held positions in Equity Research covering the biotechnology industry at Drexel Burnham Lambert and Donaldson, Lufkin & Jenrette.  He is a co-founder and Chairman of the Board of Directors of Exelixis, Inc., and a member of the Board of Directors at Biogen Idec, Inc., BG Medicine, Inc. and Joule Unlimited.  Additionally, Dr. Papadopoulos was a co-founder and former Board member of Cellzome, Inc. (acquired by GSK in 2012) and Anadys Pharmaceuticals, Inc. (acquired by Roche in 2011). 

Before joining Wall Street, he was on the faculty of the Department of Cell Biology at New York University Medical Center.  Dr. Papadopoulos is also deeply involved in the non-profit sector.  He is a co-founder and Chairman of Fondation Sante, a charitable foundation for scientific and educational purposes, and serves on the Board of Visitors at Duke University Medical Center.  Dr. Papadopoulos holds a Ph.D. in biophysics and an M.B.A. in finance, both from New York University.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals and Isis Pharmaceuticals.  Regulus is developing RG-101 for the treatment of HCV and is advancing other microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
2. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
3. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
4. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
5. Regulus to Present at Future Leaders in the Biotech Industry Conference
6. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
7. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
8. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
9. Regulus to Present at Two Upcoming Investor Conferences
10. Regulus Appoints Mark G. Foletta to its Board of Directors
11. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... -- CaryRx, a next-generation full-service pharmacy, has announced the launch ... the Washington D.C. metropolitan area. CaryRx ... of medications through the convenience of its patient-friendly mobile app. ... one hour to any location in D.C. ... service to Washington D.C. ," says Areo ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
Breaking Medicine Technology:
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... luxurious collection of unique masks and serums that perfectly fuse the beauty of ... advancements, at the 2017 Indie Beauty Expo on August 23rd & 24th in ...
(Date:8/22/2017)... ... 2017 , ... The old adage “you are what you ... healthy foods. But this well-known piece of nutrition advice ignores that an individual’s ... not only on properties of the food but also on properties of the ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... pleased to announce the addition of Zack Tisch as the firm’s new Consulting ... KLAS-ranked healthcare IT consulting firm’s national accounts, from assisting clients with initial vendor ...
(Date:8/22/2017)... CA (PRWEB) , ... August 22, 2017 , ... ... cycle management (RCM) solutions, announced recently the availability of a new professional fee ... in appreciation for their service to the healthcare industry. E/M coding is complex ...
(Date:8/22/2017)... DFW Metroplex, TX (PRWEB) , ... August 22, 2017 , ... Five Star Glass is ... They provide repair and replacement of auto glass for most makes and models, in ... area in the USA. , They have been a family owned business for the ...
Breaking Medicine News(10 mins):